www.horizonscan.nl gebruikt cookies om het gebruik van de website te analyseren en het gebruiksgemak te verbeteren. Lees meer over cookies op www.rijkshuisstijl.nl
Sluiten
Published on 8 December 2020
ADHD
ALL
ALS
AML / MDS
Azacitidine
AML post-intensive chemotherapy maintenance therapy for patients in complete remission
Geïndiceerd voor de behandeling van volwassen patiënten die niet in aanmerking komen voor
hematopoëtische stamceltransplantatie (HSCT), met:
• intermediair 2 en hoog risico myelodysplastische syndromen (MDS) volgens het International Prognostic Scoring System (IPSS),
• chronische myelomonocytaire leukemie (CMML) met 10%-29% beenmergblasten zonder
myeloproliferatieve aandoening,
• acute myeloïde leukemie (AML) met 20%-30% blasten en multilineaire dysplasie, volgens de
indeling van de Wereldgezondheidsorganisatie (WHO).
• AML met >30% beenmergblasten volgens de indeling van de WHO.
G
Geïndiceerd voor de behandeling van volwassen patiënten die niet in aanmerking komen voor
hematopoëtische stamceltransplantatie (HSCT), met:
• intermediair 2 en hoog risico myelodysplastische syndromen (MDS) volgens het International Prognostic Scoring System (IPSS),
• chronische myelomonocytaire leukemie (CMML) met 10%-29% beenmergblasten zonder
myeloproliferatieve aandoening,
• acute myeloïde leukemie (AML) met 20%-30% blasten en multilineaire dysplasie, volgens de
indeling van de Wereldgezondheidsorganisatie (WHO).
• AML met >30% beenmergblasten volgens de indeling van de WHO.
G
Geïndiceerd voor de behandeling van volwassen patiënten die niet in aanmerking komen voor hematopoëtische stamceltransplantatie (HSCT), met:
• intermediair 2 en hoog risico myelodysplastische syndromen (MDS) volgens het International Prognostic Scoring System (IPSS),
• chronische myelomonocytaire leukemie (CMML) met 10%-29% beenmergblasten zonder myeloproliferatieve aandoening,
• acute myeloïde leukemie (AML) met 20%-30% blasten en multilineaire dysplasie, volgens de indeling van de Wereldgezondheidsorganisatie (WHO).
• AML met >30% beenmergblasten volgens de indeling van de WHO.
G
Gilteritinib
Glasdegib
Guadecitabine
Idasanutlin
Imetelstat
Iomab-B
Luspatercept
Sapacitabine
Venetoclax
IND
Aggressive non-Hodgkin's lymphoma
Allergy
Antithrombotic medications
Asthma
Bacterial infections
Bipolar disorder
Bladder cancer
Bowel diseases
Brain cancer
Breast cancer
CLL
COPD
Cardiovascular diseases
Colon cancer
Cystic fibrosis
Bamocaftor / tezacaftor / ivacaftor
Elexacaftor / tezacaftor / ivacaftor
Ivacaftor
Kalydeco tablets are indicated for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (CF) who have an R117H CFTR mutation or one of the following gating (class III) mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R .
IND
Extension of indication to extend the indication of Kalydeco (ivacaftor) tablets in combination regimen with Kaftrio (ivacaftor/tezacaftor/elexacaftor) tablets for the treatment of adults and adolescents aged 12 years and older with cystic fibrosis (CF) who have at least one F508del mutation in the CFTR gene.
IND
Kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (CF) who have an R117H CFTR mutation or one of the following gating (class III) mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R
IND
Tezacaftor / ivacaftor
Symkevi is indicated in a combination regimen with ivacaftor 150 mg tablets for the treatment of patients with cystic fibrosis (CF) aged 12 years and older who are homozygous for the F508del mutation or who are heterozygous for the F508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: P67L, R117C, L206W, R352Q, A455E, D579G, 711+3A→G, S945L, S977F, R1070W, D1152H, 2789+5G→A, 3272-26A→G, and 3849+10kbC→T.
Symkevi is indicated in a combination regimen with ivacaftor 150 mg tablets for the treatment of patients with cystic fibrosis (CF) aged 6 years and older who are homozygous for the F508del mutation or who are heterozygous for the F508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: P67L, R117C, L206W, R352Q, A455E, D579G, 711+3A→G, S945L, S977F, R1070W, D1152H, 2789+5G→A, 3272‑26A→G, and 3849+10kbC→T.
IND
Dementia
Depression
Diabetes
Duchenne
Epilepsy
Eye disorders
Head and neck cancer
Headache
Hearing disorders
Hematology other
Hodgkin's lymphoma
Hormonal disorders
Indolent non-Hodgkin's lymphoma
Kidney cancer
Leukemia
Lipid-lowering medications
Liver cancer
Liver diseases
Lung cancer
Mesothelioma
Multiple Myeloma
Multiple sclerosis
Muscular diseases
Myeloproliferative disorders
Neuroendocrine cancer
Other chronic immune diseases
Other infectious diseases
Other lung
Other medication for cardiovascular diseases
Other muscular diseases
Other neurological disorders
Other non-oncological hematological medications
Other oncology
Ovarian cancer
Pain
Pancreatic cancer
Parkinson's
Prostate cancer
Rheumatism
SMA
Schizophrenia, psychosis
Skin cancer
Skin diseases
Sleep disorders
Stem cell transplants
Stomach cancer
Thyroid cancer
Unknown
Viral infections
Naar boven